Date: May 28, 2021  Administrative Circular: 2021:21

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products
COVID-19 Vaccines

COVID-19 mRNA Vaccine BNT162b2 (Pfizer)
The product page has been revised as follows:

- **Doses and Schedules:**
  - The interval between dose 1 and 2 has been revised to 21 days with additional content to Footnote C to indicate that this is the authorized Health Canada schedule, however, the current interval in BC is based on vaccine supply and operational recommendations as outlined on the government of BC website. As of May 27, 2021, the recommended interval between dose 1 and 2 is 8 weeks.

  Please remove page numbers: 1-5 dated May 20, 2021
  Please add new page numbers: 1-5 dated May 28, 2021

COVID-19 mRNA Vaccine mRNA-1273 (Moderna)
The product page has been revised as follows:

- **Doses and Schedules:**
  - The interval between dose 1 and 2 has been revised to 28 days with additional content to Footnote D to indicate that this is the authorized Health Canada schedule, however, the current interval in BC is based on vaccine supply and operational recommendations as outlined on the government of BC website. As of May 27, 2021, the recommended interval between dose 1 and 2 is 8 weeks.

  Please remove page numbers: 1-4 dated May 20, 2021
  Please add new page numbers: 1-4 dated May 28, 2021
COVID-19 Vaccine (ChAdOx1-S [recombinant]) (AstraZeneca/Verity Pharmaceuticals)
The product page has been revised as follows:

- **Doses and Schedules:**
  - The interval between dose 1 and dose 2 has been revised to 8 to 12 weeks apart.
  - Footnote D has been revised to indicate that the preferred interval is 8 to 12 weeks.

- **Adverse Events:**
  - The onset of most cases of serious blood clots following receipt of the AstraZeneca or COVISHIELD vaccine has been revised to 4 to 28 days.
  - The frequency of Thrombosis with Thrombocytopenia Syndrome following a second dose of vaccine has been added.

Please remove page numbers: 1-4 dated May 20, 2021
Please add new page numbers: 1-4 dated May 28, 2021

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)
The product page has been revised as follows:

- **Adverse Events:**
  - The onset of most cases of serious blood clots following receipt of the Janssen vaccine has been revised to 4 to 28 days.

Please remove page numbers: 1-4 dated May 20, 2021
Please add new page numbers: 1-4 dated May 28, 2021
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division